RET and lung cancer: To our knowledge, this is the first report of a novel <i>ISOC1-RET</i> fusion lung cancer with a durable complete response to selpercatinib, with resistance via <i>MET</i> amplification, which was overcome by the successful combination of selpercatinib and capmatinib.